ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1855

Evaluating the OMERACT Definitions of Ultrasound Gout Structural Lesions in the Diagnosis of Gout

Sara Nysom Christiansen1, Mikkel Østergaard 2, Ole Slot 1 and Lene Terslev 3, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Glostrup, Denmark, 2Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, 3Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen, Denmark

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: gout and Sodium Urate Crystals, Ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: 4M111: Imaging of Rheumatic Diseases I (1854–1859)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: To evaluate ultrasound (US) as a diagnostic tool for gout with positive urate crystal microscopy as the gold standard, using the OMERACT US working group definitions for crystal deposits.

Methods: US examinations (28 joints, 26 tendons) were performed in patients with clinically suspected gout. Joints (metacarpophalangeal, wrist, elbow, metatarsophalangeal, tibiotalar and knee joints) and tendons (extensor tendons of the wrist (scored as compartments (1-6)), triceps, quadriceps, patella, peroneus (longus and brevis scored as one), tibialis posterior and Achilles) were evaluated for the OMERACT gout structural lesions (double contour (DC), tophus, aggregates and erosions). Each of the structural lesions were registered as present/absent for each patient. The US assessment was compared to the gold standard reference for gout: presence/absence of monosodium-urate (MSU) crystals at joint fluid microscopy. The microscopies were performed by a rheumatologist blinded to US findings.

The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of each US lesion, with microscopy as gold standard, were evaluated.

Results: 82 patients (70 males, 12 females), mean age of 61 years (19-88) were included. 57 had a positive microscopy for MSU crystals, 23 patients had a negative microscopy and in 2 patients joint aspiration was not possible (table 1).
All four structural lesions were statistically significant more frequent in patients with positive MSU microscopy compared to patients with negative microscopy (Fisher’s exact test with p-values from < 0.0001 to 0.0049), and all lesions were found to have high sensitivities for gout (ranges from 0.77-0.95). DC and tophus showed high specificities for patients with microscopically verified gout (0.88 and 0.92, respectively) and were also found to have high PPV (0.94 and 0.96, respectively). Low specificities were found for both aggregates and erosions (0.40 and 0.56). Negative predictive values were low to moderate for all lesions (ranges from 0.52-0.77).

Conclusion: The OMERACT set of US definitions of structural gout lesions seems to be a valid tool for diagnosis of gout in clinical practice. Particularly, DC and tophi seem to have a high specificity and high PPV for the disease, when joint fluid microscopy is considered as gold standard.


Disclosure: S. Christiansen, None; M. Østergaard, AbbVie, 2, 8, 9, Abbvie, 2, 5, 8, Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, UCB, 5, 8, Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB, 5, 8, Abbvie, Celgene, Centocor, Merck, and Novartis, 2, Abbvie, Celgene, Centocor, Merck, Novartis, 2, BMS, 2, 5, 8, 9, Boehringer Ingelheim, 5, 8, Boehringer-Ingelheim, 2, 8, Boehringer-ingelheim, 9, Celgene, 2, 5, 8, Centocor, 2, Eli Lilly, 5, 8, 9, Eli Lilly and Company, 5, 8, Eli-Lilly, 2, 8, Hospira, 2, 5, 8, Janssen, 2, 5, 8, 9, Merck, 2, 5, 8, 9, Novartis, 2, 5, 8, Novo, 2, 5, 8, Novo Nordisk, 5, 8, Orion, 2, 5, 8, Pfizer, 2, 5, 8, 9, Regeneron, 2, 5, 8, Roche, 2, 5, 8, roche, 9, Sandoz, 2, 8, Sanofi, 2, 8, UCB, 2, 5, 8; O. Slot, None; L. Terslev, None.

To cite this abstract in AMA style:

Christiansen S, Østergaard M, Slot O, Terslev L. Evaluating the OMERACT Definitions of Ultrasound Gout Structural Lesions in the Diagnosis of Gout [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/evaluating-the-omeract-definitions-of-ultrasound-gout-structural-lesions-in-the-diagnosis-of-gout/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluating-the-omeract-definitions-of-ultrasound-gout-structural-lesions-in-the-diagnosis-of-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology